Join our investing community

Trading STI: Trading Halt with interesting reasons

Discussion in 'Shares' started by wdongli, 10th Jun, 2011.

  1. wdongli

    wdongli Well-Known Member

    31st Mar, 2010
    STI just asked trading halt after the market closed. It gives the reasons as below:

    1. Company strategic review advice
    2. Telemedcare and Stirling Pharma progress and developments
    3. First exclusive HDA platform licensing for the pulmonary delivery of a major drug.
    4. Proposed UK AIM listing and funding

    For HDA pulmonary delivery device, an article would be helpful:
    Stirling Products increases product - One News Page [Aus] Business

    Stirling Products increases product coverage with feature in ONdrugDelivery
    Proactive Investors, Monday, 2 May 2011

    Stirling Products (ASX: STI) has attracted attention with a feature in a specialist industry publication, ONdrugDelivery, about the company’s patented High Density Aerosol (HDA) pulmonary drug delivery device. The publication focuses on pulmonary and nasal drug delivery and has a readership base of 40,000 worldwide mainly within the pharmaceutical and biotechnology industry sectors.

    Dry powder based drug delivery device

    1. Stirling’s HDA product differs from other pulmonary drug delivery devices as most are a dry-powder base.

    2. Highlighting the future impact of HDA’s within the industry, the article notes that Pfizer’s (NYSE: PFE) ‘Exubera’ was the next generation dry-powder delivery technology where more than “US$1 billion was reportedly written off when this project was abandoned.”

    3. Despite the knowledge that the lungs have naturally inbuilt defences which reject powders, essentially a dust, there remains a focus on dry-powder systems in the industry.

    A potential breakthrough

    1. The problems associated with dry-powders positions Stirling to make a potential breakthrough in the industry. The company is in the process of commercializing a better drug delivery system to the lungs with a “new class of aerosol – generation device that is suited for use in a wide range of applications.”

    2. The article notes “This HDA technology has proven it is highly efficient in delivering respiratory drugs such as albuterol sulphate.”

    3. Albuterol is used in inhalation devices worldwide to combat asthma and chronic obstructive pulmonary disease.

    4. Stirling’s HDA Nebuliser device can deliver the drug deep into the lung in a dissolved state that helps the lungs quickly absorb more of the drug.

    5. The company’s device illustrates technology that offers advantages such as true breath-activation and that it can be used for multiple drug products.

    3M sponsored

    This particular ONdrugDelivery issue has been sponsored by the 3M Company (NYSE: MMM) and will be distributed at the Respiratory Drug Delivery Conference being held over four days this week in Berlin.

    The conferences are designed for those involved in the development, investigation, preparation and delivery of old and new therapeutic entities by aerosol systems.

    The conference will have over 50 industry exhibitors as well as 70 scientific posters with most of them focused on developments and opportunities within the rapidly developing respiratory drug delivery market.

    STI has all of characteristics, high risk vs high return in normal market conditions. The selling season and the 22-month-correction in Australia stock market perhaps have made it low risk vs high return fallen angel since its price has dropped down significantly and successfully made its old shareholders in great pains. All of biotech swans usually come out of the deep water after a lot losses of its shareholders' capitals or money.




    Actually it has kept to be sold by its old shareholders on fire since May 2009 and quite lot of its shareholders have given up any hopes. I like the hopeless mood of market players very much, and then I bought in at $0.004 and failed to get it at lowest price as I hoped. Could it be another PRR? Perhaps not but if its price could come back to $0.05, it would be quite nice. Who knows?

    No one really know since it is a dirty-cheap fish, the market orphan, no decent and qualitative people like to touch it! You need to be brave, good senses about the worst time in your horizon, sympathy soul, and affordable capital to touch it but you could be extremely unlucky! Anyway it has been hit by the market for more than a decade. It is really miserable from the darling to the dog! I am happy I didn't buy it more than $0.02.
    Last edited by a moderator: 10th Jun, 2011